CN103611195A - Self-adhesion hemostasis anti-adhesion corpus fibrosum - Google Patents
Self-adhesion hemostasis anti-adhesion corpus fibrosum Download PDFInfo
- Publication number
- CN103611195A CN103611195A CN201310593829.2A CN201310593829A CN103611195A CN 103611195 A CN103611195 A CN 103611195A CN 201310593829 A CN201310593829 A CN 201310593829A CN 103611195 A CN103611195 A CN 103611195A
- Authority
- CN
- China
- Prior art keywords
- self
- adhesion
- corpus fibrosum
- carboxymethyl chitosan
- bleeding stopping
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The invention discloses a self-adhesion hemostasis anti-adhesion corpus fibrosum which comprises organic polymers and carboxymethyl chitosan, wherein the organic polymers are selected from poly(lactic-co-glycolic acid) copolymer, polylactic acid, polylactic acid-polyethylene glycol block copolymer, polycarprolactone-glycolic acid copolymer and polycarprolactone. The self-adhesion hemostasis anti-adhesion corpus fibrosum has enough mechanical strength, can stop bleeding and prevent adhesion, and is suitable for hemostasis anti-adhesion treatment of active hemorrhage.
Description
Technical field
The present invention relates to medical anti-adhesion material technical field, relate in particular to a kind of self-adhesion bleeding stopping and adherence preventing corpus fibrosum.
Background technology
Postoperative intestinal adhesion is domestic and international surgical field one of unsolved important difficult medical problem still so far.Adhesion not only can cause serious complication, and bad adhesion is also the one of the main reasons that complication obviously increases while again performing the operation.Want efficiently to treat adhesion, mechanism that first should clear and definite adhesion, fundamentally starts with and deals with problems.Research shows, when tissue sustains damage, can cause that cell discharges a large amount of histamine and cytokine, and these materials can cause local inflammation reaction.Meanwhile, blood vessel oozes out fibrin, forms network structure, and then causes the deposition of fibrous tissue and albumen.Now have two kinds of possible phenomenons to occur, first plasminogen activates, and makes fibrinolysis, thereby causes normal agglutination; It two is if plasminogen is suppressed, can form fibrin structure, sticks together.So should stop blooding in time, fundamentally prevent the generation of adhesion.
Desirable adherence preventing material should have low irritability, suitable tissue adherence; Complete wound coverage surface and there is retention time in enough bodies; Can degraded and absorbed and do not need second operation to be taken out; Wound healing; There is certain mechanical strength simultaneously and be convenient to implementation and operation etc.Existing adherence preventing material, the especially membrane material of having gone on the market, although preventing adhesiving effect is definite, has clear and definite contraindication, i.e. infected wound and active hemorrhage wound forbidding.Research shows, gel has local hemostasis effect and suppresses fibrin bundle and forms, thereby has reduced the tissue adhesion who causes because of organization of hematoma.Have that selectivity promotes epithelial cell, endothelial cell growth and the biological nature that is suppressed to fibroblast growth simultaneously, thereby promote the reparation of tissue physiology's property, suppress cicatrization, reduce tissue adhesion.But the mechanical strength of gel is poor, is not easy to body and is implanted into the long-term maintenance with form.
Therefore, we urgently find anti fibrous material prepared by a kind of suitable composite high-molecular material at present, and prepared material has suitable mechanical strength, simultaneously can bleeding stopping and adherence preventing, realize efficiently treatment, and reach the effect of hemostasis, prevention of postoperative adhesion.We show hemorrhage and the compound generation that can effectively stop postoperative active hemorrhage of adherence preventing material in the research in early stage, but for the selection of hemorrhage consumption, how better for the metabolic problems of residual hemorrhage in different wound surface release and the rear Antiadhesive film that stopped blooding, to never have and to solve.How better hemostasis gel to be combined with adherence preventing material to use and bring into play its effect separately, retain the mechanical strength of adherence preventing material and the hemostatic function of hemostasis gel, blood coagulation is locked in not to be lured into fibroblast into and adheres in material, do not affect mesothelial cell's healing simultaneously, being the key of material Choice and design, is also the key as bleeding stopping and adherence preventing material.
Summary of the invention
The object of the present invention is to provide a kind of self-adhesion bleeding stopping and adherence preventing corpus fibrosum, it possesses enough mechanical strengths, simultaneously can bleeding stopping and adherence preventing, the hemostasis of applicable active hemorrhage and anti treatment.
For realizing object of the present invention, provide following technical scheme:
A self-adhesion bleeding stopping and adherence preventing corpus fibrosum, comprising:
Be selected from the organic polymer of Poly(D,L-lactide-co-glycolide, polylactic acid, polylactic acid-polyethylene glycol block copolymer, polycaprolactone-co-glycolic acid and polycaprolactone; With
Carboxymethyl chitosan.
In self-adhesion bleeding stopping and adherence preventing corpus fibrosum of the present invention, Poly(D,L-lactide-co-glycolide (poly (lactic-co-glycolic acid), PLGA), by two kinds of monomers---lactic acid (Lactic acid, LA) and hydroxyacetic acid (glycolic acid, GA) be polymerized at random, it is a kind of degradable functional polymer organic compound, there is good biocompatibility, nontoxic, good encystation and the performance of film forming, be widely used in pharmacy, medical engineering material and modernization industry field, at U.S. PLGA, pass through (the Food and Drug Administration of food and drug administration, FDA) authentication, formally as pharmaceutic adjuvant, included into American Pharmacopeia.The ratio of two kinds of monomers---lactic acid and hydroxyacetic acid is different can prepare dissimilar PLGA, for example: PLGA75:25 represents that this polymer is comprised of 75% lactic acid and 25% hydroxyacetic acid.Polylactic acid (polylactic acid, PLA) claim again polylactide, to take the polymer that lactic acid obtains as primary raw material polymerization, raw material sources fully and can regenerate, the production process of polylactic acid is pollution-free, and product can biodegradation, realize the circulation at occurring in nature, be therefore desirable Green Polymer Material.Polylactic acid-polyethylene glycol block copolymer, by polylactic acid and Polyethylene Glycol (polyethylene glycol, PEG) copolymerization forms, it is degradable medical material, there is at present several different methods to prepare, such as Chinese invention patent publication No. CN102702535A discloses a kind of process of creatinine catalyzing and synthesizing polylactic acid-polyethyleneglycol block copolymer.Polycaprolactone-co-glycolic acid, claim again Acetic acid, hydroxy-, bimol. cyclic ester-epsilon-caprolactone copolymer (poly (glycolide-co-ε-caprolactone), PGCL), Acetic acid, hydroxy-, bimol. cyclic ester (glycollide, GA) and ε-caprolactone (ε-caprolactone, CL) copolymer, as biodegradable macromolecular material, in the research and development of medical macromolecular materials, occupy critical role, at operation suture thread, artificial skin and blood vessel, skeletal fixation and reparation, medicine, control many fields such as release, organizational project and obtained application.By controlling the ratio of glycolide monomer and ε-caprolactone monomer, can obtain the Acetic acid, hydroxy-, bimol. cyclic ester caprolactone copolymer of Different Weight ratio.Polycaprolactone (Polycaprolactone, PCL), at metallo-organic compound (as tetraphenyltin), to make catalyst by 6-caprolactone, dihydroxy or trihydroxy are done ring-opening polymerisation under initiator condition and are formed, belong to aggretion type polyester, its molecular weight is different and different with consumption with the kind of starting material from discrimination degree.
Carboxymethyl chitosan (Carboxymethyl chitosan) is a kind of water-solubility chitosan derivative, has numerous characteristics, as antibiotic property is strong, has preservation, is a kind of polyampholyte etc.Its main pharmacological comprises antibacterial infection, blood fat reducing and prevents and treats arteriosclerosis, antiviral, antitumor, anticoagulation, blood sugar lowering, at cosmetics, the aspect such as fresh-keeping and medical, has multiple application.Muzzarelli etc. are just fully recognized that in five sixties chemical constitution of sulfated chitosan is similar to heparin, indicate that this compounds has anticoagulant active.Hirano report in 1985, the anticoagulant active of the two sulfuric ester carboxymethyl chitosans in O-position of molecular weight 26000 is 1.9～2.2 times of heparin (174 unit/milligram).
Preferably, described organic macromolecule weight average molecular weight is 5～500,000, for example 50,000,60,000,80,000,100,000,120,000,150,000,180,000,200,000,240,000,250,000,270,000,300,000,320,000,350,000,380,000,400,000,420,000,450,000,480,000,490,000 or 500,000.
Preferably, the weight average molecular weight of described carboxymethyl chitosan is 1～80,000, for example 10,000,20,000,30,000,40,000,50,000,60,000,70,000 or 200,000.
Preferably, in described self-adhesion bleeding stopping and adherence preventing corpus fibrosum, also comprise calcium chloride.
As an optimal technical scheme of the present invention, described self-adhesion bleeding stopping and adherence preventing corpus fibrosum makes by the following method:
(1) described organic polymer is made to complex fiber material by high-voltage electrostatic spinning;
(2) described complex fiber material is soaked to 1-5 hour in the aqueous solution of carboxymethyl chitosan and calcium chloride, after lyophilization, hot pressing 15-60 minute under 40-85 ℃ of condition, obtains described self-adhesion bleeding stopping and adherence preventing corpus fibrosum.
Wherein, in described step (2), soak time can be 1 hour, 2 hours, 3 hours, 4 hours or 5 hours; Hot pressing temperature can be 42 ℃, 45 ℃, 50 ℃, 55 ℃, 60 ℃, 65 ℃, 70 ℃, 75 ℃, 80 ℃ or 84 ℃; Hot pressing time can be 15 minutes, 18 minutes, 25 minutes, 30 minutes, 40 minutes or 50 minutes; Preferably 50 ℃ of hot pressing is 20 minutes.
Preferably, described step (1) is specially:
(1a) described organic polymer is dissolved in organic solvent, being mixed with concentration is 20-50%(W/V) organic polymer solution;
(1b) described organic polymer solution being injected to syringe, add rustless steel syringe needle, is 10-30KV at voltage, solution flow rate is 1-5mL/h, under the condition that receiving range is 5-25cm, carries out electrostatic spinning and obtains complex fiber material, room temperature vacuum drying 24-48 hour, removes residual solvent.
More preferably, described organic solvent is DMF (N, N-Dimethylformamide, DMF), the mixing of a kind of in acetone, oxolane (Tetrahydrofuran, THF) and hexafluoroisopropanol (Hexafluoroisopropanol, HFIP) or at least two kinds.The example of the typical case of described mixing but indefiniteness is such as DMF and acetone, THF and acetone, DMF, THF and acetone etc.
Wherein, the concentration of organic polymer solution can be: 20%(W/V), 25%(W/V), 28%(W/V), 30%(W/V), 32%(W/V), 35%(W/V), 38%(W/V), 42%(W/V), 45%(W/V) or 48%(W/V), wherein wt (W) is in unit gram (g), volume (V) is in unit milliliter (mL), and weight/volume (W/V) is in unit grams per milliliter (g/mL).
Preferably, in described step (1b), voltage can be 12KV, 15KV, 18KV, 22KV, 25KV, 27KV or 29KV; Solution flow rate can be 1.5mL/h, 2mL/h, 2.5mL/h, 3mL/h, 3.5mL/h, 4mL/h or 4.5mL/h; Receiving range can be 6cm, 7cm, 9cm, 11cm, 13cm, 15cm, 17cm, 19cm, 21cm, 23cm or 24cm; Can be 25 hours, 27 hours, 30 hours, 35 hours, 38 hours, 40 hours, 42 hours, 44 hours, 46 hours or 47 hours drying time.
Preferably, in the aqueous solution of described carboxymethyl chitosan and calcium chloride, the concentration of carboxymethyl chitosan is 2-6%(W/V), 2%(W/V for example), 3%(W/V), 4%(W/V), 5%(W/V) or 6%(W/V), the concentration of calcium chloride is 5-20%(W/V), 6%(W/V for example), 8%(W/V), 12%(W/V), 15%(W/V), 18%(W/V) or 19%(W/V).
More preferably, the aqueous solution of described carboxymethyl chitosan and calcium chloride is prepared by the following method: by the carboxymethyl chitosan concentration that is mixed with soluble in water, be 1-3%(W/V) aqueous solution, stirring at room also drips saturated calcium chloride water, then add carboxymethyl chitosan, the final concentration that makes carboxymethyl chitosan is 2-6%(W/V), the final concentration of calcium chloride is 5-20%(W/V).
As a most preferred technique scheme of the present invention, described self-adhesion bleeding stopping and adherence preventing corpus fibrosum makes by the following method:
(1 ') is dissolved in N by the organic polymer that is selected from Poly(D,L-lactide-co-glycolide, polylactic acid, polylactic acid-polyethylene glycol block copolymer, polycaprolactone-co-glycolic acid and polycaprolactone, the organic solvent of the mixing of a kind of in dinethylformamide, acetone, oxolane and hexafluoroisopropanol or at least two kinds, being mixed with concentration is 20-50%(W/V) organic polymer solution;
(2 ') injects syringe by described organic polymer solution, adds rustless steel syringe needle, at voltage, is 10-30KV, solution flow rate is 1-5mL/h, under the condition that receiving range is 5-25cm, carries out electrostatic spinning and obtains complex fiber material, room temperature vacuum drying 24-48 hour, removes residual solvent;
(3 ') is 1-3%(W/V by the carboxymethyl chitosan concentration that is mixed with soluble in water) aqueous solution, stirring at room also drips saturated calcium chloride water, then add carboxymethyl chitosan, the final concentration that obtains carboxymethyl chitosan is 2-6%(W/V), the final concentration of calcium chloride is 5-20%(W/V) mixed solution; With
(4 ') soaks described complex fiber material 2 hours in described mixed solution, lyophilization 24-48 hour, and then hot pressing 20 minutes in the heating platen of 50 ℃, obtains described self-adhesion bleeding stopping and adherence preventing corpus fibrosum.
Beneficial effect of the present invention is: self-adhesion bleeding stopping and adherence preventing corpus fibrosum of the present invention, by carboxymethyl chitosan hot pressing physical crosslinking, and compound with the complex fiber material of anti, effectively keep primary characteristic, the carboxymethyl chitosan of hot pressing physical crosslinking can quick-gelatinizing when meeting active hemorrhage, fits tightly with wound surface, form the haemostatic effect of physics extruding, two sulfuric esters on molecule can activate thrombin simultaneously, and further hemostasis, does not produce metabolism hidden danger simultaneously; After active hemorrhage stops, blood coagulation is covered by carboxymethyl chitosan gel, and after about 2 hours, gel is diluted absorption gradually, and the complex fiber material of remaining anti does not affect wound surface mesothelial cell to be repaired, and further plays the effect of post-operation adhesion preventing.
Accompanying drawing explanation
Fig. 1 adopts the self-adhesion bleeding stopping and adherence preventing corpus fibrosum of the embodiment of the present invention 1 preparation active hemorrhage model mouse to be carried out to the result figure of wound dressing.
The specific embodiment
Below in conjunction with embodiment, embodiment of the present invention are described in detail.It will be understood to those of skill in the art that following examples are only the preferred embodiments of the present invention, so that understand better the present invention, thereby should not be considered as limiting scope of the present invention.For a person skilled in the art, the present invention can have various modifications and variations, within the spirit and principles in the present invention all, any modification of doing, is equal to and replaces or improvement etc., within all should being included in protection scope of the present invention.Experimental technique in following embodiment, if no special instructions, is conventional method; Experiment material used, if no special instructions, is and is purchased available from routine biochemistry chemical reagent work.
Embodiment 1:
The present embodiment is prepared as follows the anti corpus fibrosum with self-adhesion hemostatic function:
(1) preparation organic polymer mixed solution: by PLGA(Mw=8 ten thousand, LA/GA=75/25) be dissolved in DMF/ acetone mixed solvent (volume ratio 1/1 of DMF/ acetone), being mixed with concentration is 30%(W/V) organic polymer mixed solution, stirring at room 12 hours.
(2) prepare anti fibrous material: the syringe that the organic polymer mixed solution of step (1) preparation is injected respectively to 10 10mL, add rustless steel syringe needle No. 5, at voltage, be 25KV, solution flow rate is 1.5mL/h, receiving range is to carry out multi-nozzle electrospinning 40 minutes under the condition of 18cm, obtains complex fiber material, room temperature vacuum drying 24-48 hour, remove residual solvent, fiber film material thickness is 100-140 micron.
(3) solution 10mL preparation hemostatic material solution: it is 2%(W/V that the water-soluble solution preparation of carboxymethyl chitosan (Mw=25000) 200mg is become to concentration), stirring at room slowly drips saturated CaCl
2aqueous solution 1mL, speed control is 1mL/h; After this add carboxymethyl chitosan 100mg, the concentration that makes final carboxymethyl chitosan is 3%, CaCl
2concentration is 12%.
(4) prepare self-adhesion bleeding stopping and adherence preventing corpus fibrosum composite: complex fiber material prepared by step (2) is soaked in the hemostatic material solution of step (3), be placed in surface plate after 2 hours, directly lyophilization is 24 hours, after taking-up, in 50 ℃ of heating platens, hot pressing is 20 minutes, obtains self-adhesion bleeding stopping and adherence preventing corpus fibrosum.
Embodiment 2:
The present embodiment is prepared as follows the anti corpus fibrosum with self-adhesion hemostatic function:
(1) preparation organic polymer mixed solution: by PLA(Mw=5 ten thousand) be dissolved in DMF/ acetone mixed solvent (volume ratio 1/1 of DMF/ acetone), being mixed with concentration is 20%(W/V) organic polymer mixed solution, stirring at room 8 hours.
(2) prepare anti fibrous material: the syringe that the organic polymer mixed solution of step (1) preparation is injected respectively to 10 10mL, add rustless steel syringe needle No. 5, at voltage, be 10KV, solution flow rate is 5mL/h, receiving range is to carry out multi-nozzle electrospinning 40 minutes under the condition of 25cm, obtains complex fiber material, room temperature vacuum drying 24 hours, remove residual solvent, fiber film material thickness is 100-120 micron.
(3) solution 10mL preparation hemostatic material solution: it is 1%(W/V that the water-soluble solution preparation of carboxymethyl chitosan (Mw=10000) 100mg is become to concentration), stirring at room slowly drips saturated CaCl
2aqueous solution 0.5mL, speed control is 1mL/h; After this add carboxymethyl chitosan 100mg, the concentration that makes final carboxymethyl chitosan is 2%, CaCl
2concentration is 6%.
(4) prepare self-adhesion bleeding stopping and adherence preventing corpus fibrosum composite: complex fiber material prepared by step (2) is soaked in the hemostatic material solution of step (3), be placed in surface plate after 2 hours, directly lyophilization is 48 hours, after taking-up, in 40 ℃ of heating platens, hot pressing is 60 minutes, obtains self-adhesion bleeding stopping and adherence preventing corpus fibrosum.
Embodiment 3:
The present embodiment is prepared as follows the anti corpus fibrosum with self-adhesion hemostatic function:
(1) preparation organic polymer mixed solution: by PGCL(Mw=50 ten thousand, CL/GA=75/25) be dissolved in DMF/ acetone mixed solvent (volume ratio 1/1 of DMF/ acetone), being mixed with concentration is 50%(W/V) organic polymer mixed solution, stirring at room 15 hours.
(2) prepare anti fibrous material: the syringe that the organic polymer mixed solution of step (1) preparation is injected respectively to 10 10mL, add rustless steel syringe needle No. 5, at voltage, be 30KV, solution flow rate is 1mL/h, receiving range is to carry out multi-nozzle electrospinning 60 minutes under the condition of 5cm, obtains complex fiber material, room temperature vacuum drying 48 hours, remove residual solvent, fiber film material thickness is 150-180 micron.
(3) solution 10mL preparation hemostatic material solution: it is 4%(W/V that the water-soluble solution preparation of carboxymethyl chitosan (Mw=80000) 400mg is become to concentration), stirring at room slowly drips saturated CaCl
2aqueous solution 1.5mL, speed control is 1mL/h; After this add carboxymethyl chitosan 200mg, the concentration that makes final carboxymethyl chitosan is 6%, CaCl
2concentration is 18%.
(4) prepare self-adhesion bleeding stopping and adherence preventing corpus fibrosum composite: complex fiber material prepared by step (2) is soaked in the hemostatic material solution of step (3), be placed in surface plate after 2 hours, directly lyophilization is 48 hours, after taking-up, in 85 ℃ of heating platens, hot pressing is 15 minutes, obtains self-adhesion bleeding stopping and adherence preventing corpus fibrosum.
Embodiment 4:
The present embodiment is prepared as follows the anti corpus fibrosum with self-adhesion hemostatic function:
(1) preparation organic polymer mixed solution: by PCL(Mw=20 ten thousand) be dissolved in DMF/ acetone mixed solvent (volume ratio 2/1 of DMF/ acetone), being mixed with concentration is 35%(W/V) organic polymer mixed solution, stirring at room 10 hours.
(2) prepare anti fibrous material: the syringe that the organic polymer mixed solution of step (1) preparation is injected respectively to 10 10mL, add rustless steel syringe needle No. 5, at voltage, be 20KV, solution flow rate is 3mL/h, receiving range is to carry out multi-nozzle electrospinning 50 minutes under the condition of 15cm, obtains complex fiber material, room temperature vacuum drying 36 hours, remove residual solvent, fiber film material thickness is 110-130 micron.
(3) solution 10mL preparation hemostatic material solution: it is 2%(W/V that the water-soluble solution preparation of carboxymethyl chitosan (Mw=40000) 200mg is become to concentration), stirring at room slowly drips saturated CaCl
2aqueous solution 1mL, speed control is 1mL/h; After this add carboxymethyl chitosan 200mg, the concentration that makes final carboxymethyl chitosan is 4%, CaCl
2concentration is 12%.
(4) prepare self-adhesion bleeding stopping and adherence preventing corpus fibrosum composite: complex fiber material prepared by step (2) is soaked in the hemostatic material solution of step (3), be placed in surface plate after 2 hours, directly lyophilization is 36 hours, after taking-up, in 50 ℃ of heating platens, hot pressing is 20 minutes, obtains self-adhesion bleeding stopping and adherence preventing corpus fibrosum.
Test example 1
The result that the self-adhesion bleeding stopping and adherence preventing corpus fibrosum that adopts the embodiment of the present invention 1 preparation carries out wound dressing to active hemorrhage model mouse as shown in Figure 1.Directly, with the coated wound of moistening gauze (blank), after 5min, still there is active hemorrhage; The coated wound (85/15) of fibrous material that does not add sthptic sponge can make blood coagulation in wound surface, forms a large amount of blood coagulations; The coated wound (85/15+Chem) of sthptic sponge of chemical crosslinking, because the degree of cross linking is higher,, also can there is certain clot in gelation and poor adhesion; And self-adhesion bleeding stopping and adherence preventing corpus fibrosum of the present invention (85/15+Phys), by superfine fibre (anti fibrous material) and effectively combination of sthptic sponge (carboxymethyl chitosan of hot pressing physical crosslinking), sthptic sponge adopts physical crosslinking, can adhere to wound surface by fast rapid-result gel, after about 2 hours, be that complete gelation is diluted absorption, haemostatic effect is definite, and does not affect wound healing, can effectively reduce the generation of tissue adhesion.
Applicant's statement, the present invention illustrates detailed features of the present invention and method detailed by above-described embodiment, but the present invention is not limited to above-mentioned detailed features and method detailed, do not mean that the present invention must rely on above-mentioned detailed features and method detailed could be implemented.Person of ordinary skill in the field should understand, any improvement in the present invention is selected the selection of the equivalence replacement of component and the interpolation of auxiliary element, concrete mode etc., within all dropping on protection scope of the present invention and open scope to the present invention.
Claims (10)
1. a self-adhesion bleeding stopping and adherence preventing corpus fibrosum, comprising:
Be selected from the organic polymer of Poly(D,L-lactide-co-glycolide, polylactic acid, polylactic acid-polyethylene glycol block copolymer, polycaprolactone-co-glycolic acid and polycaprolactone; With
Carboxymethyl chitosan.
2. self-adhesion bleeding stopping and adherence preventing corpus fibrosum according to claim 1, is characterized in that, described organic macromolecule weight average molecular weight is 5～500,000.
3. self-adhesion bleeding stopping and adherence preventing corpus fibrosum according to claim 1 and 2, is characterized in that, the weight average molecular weight of described carboxymethyl chitosan is 1～80,000.
4. according to the self-adhesion bleeding stopping and adherence preventing corpus fibrosum described in claim 1-3 any one, it is characterized in that, also comprise calcium chloride.
5. according to the self-adhesion bleeding stopping and adherence preventing corpus fibrosum described in claim 1-4 any one, it is characterized in that, it makes by the following method:
(1) described organic polymer is made to complex fiber material by high-voltage electrostatic spinning;
(2) described complex fiber material is soaked to 1-5 hour in the aqueous solution of carboxymethyl chitosan and calcium chloride, after lyophilization, hot pressing 15-60 minute under 40-85 ℃ of condition, obtains described self-adhesion bleeding stopping and adherence preventing corpus fibrosum.
6. self-adhesion bleeding stopping and adherence preventing corpus fibrosum according to claim 5, is characterized in that, described step (1) is specially:
(1a) described organic polymer is dissolved in organic solvent, being mixed with concentration is 20-50%(W/V) organic polymer solution;
(1b) described organic polymer solution being injected to syringe, add rustless steel syringe needle, is 10-30KV at voltage, solution flow rate is 1-5mL/h, under the condition that receiving range is 5-25cm, carries out electrostatic spinning and obtains complex fiber material, room temperature vacuum drying 24-48 hour, removes residual solvent.
7. self-adhesion bleeding stopping and adherence preventing corpus fibrosum according to claim 6, is characterized in that, described organic solvent is the mixing of a kind of in DMF, acetone, oxolane and hexafluoroisopropanol or at least two kinds.
8. according to the self-adhesion bleeding stopping and adherence preventing corpus fibrosum described in claim 5-7 any one, it is characterized in that, in the aqueous solution of described carboxymethyl chitosan and calcium chloride, the concentration of carboxymethyl chitosan is 2-6%(W/V), the concentration of calcium chloride is 5-20%(W/V).
9. according to the self-adhesion bleeding stopping and adherence preventing corpus fibrosum described in claim 5-8 any one, it is characterized in that, the aqueous solution of described carboxymethyl chitosan and calcium chloride is prepared by the following method: by the carboxymethyl chitosan concentration that is mixed with soluble in water, be 1-3%(W/V) aqueous solution, stirring at room also drips saturated calcium chloride water, then add carboxymethyl chitosan, the final concentration that makes carboxymethyl chitosan is 2-6%(W/V), the final concentration of calcium chloride is 5-20%(W/V).
10. according to the self-adhesion bleeding stopping and adherence preventing corpus fibrosum described in claim 5-9 any one, it is characterized in that, it is prepared by the following method:
(1 ') is dissolved in N by the organic polymer that is selected from Poly(D,L-lactide-co-glycolide, polylactic acid, polylactic acid-polyethylene glycol block copolymer, polycaprolactone-co-glycolic acid and polycaprolactone, the organic solvent of the mixing of a kind of in dinethylformamide, acetone, oxolane and hexafluoroisopropanol or at least two kinds, being mixed with concentration is 20-50%(W/V) organic polymer solution;
(2 ') injects syringe by described organic polymer solution, adds rustless steel syringe needle, at voltage, is 10-30KV, solution flow rate is 1-5mL/h, under the condition that receiving range is 5-25cm, carries out electrostatic spinning and obtains complex fiber material, room temperature vacuum drying 24-48 hour, removes residual solvent;
(3 ') is 1-3%(W/V by the carboxymethyl chitosan concentration that is mixed with soluble in water) aqueous solution, stirring at room also drips saturated calcium chloride water, then add carboxymethyl chitosan, the final concentration that obtains carboxymethyl chitosan is 2-6%(W/V), the final concentration of calcium chloride is 5-20%(W/V) mixed solution; With
(4 ') soaks described complex fiber material 2 hours in described mixed solution, lyophilization 24-48 hour, and then hot pressing 20 minutes in the heating platen of 50 ℃, obtains described self-adhesion bleeding stopping and adherence preventing corpus fibrosum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310593829.2A CN103611195B (en) | 2013-11-21 | 2013-11-21 | Self-adhesion hemostasis anti-adhesion corpus fibrosum |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310593829.2A CN103611195B (en) | 2013-11-21 | 2013-11-21 | Self-adhesion hemostasis anti-adhesion corpus fibrosum |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103611195A true CN103611195A (en) | 2014-03-05 |
| CN103611195B CN103611195B (en) | 2015-04-22 |
Family
ID=50161926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310593829.2A Active CN103611195B (en) | 2013-11-21 | 2013-11-21 | Self-adhesion hemostasis anti-adhesion corpus fibrosum |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103611195B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104383581A (en) * | 2014-11-12 | 2015-03-04 | 无锡中科光远生物材料有限公司 | Wound protecting composition with bleeding-stopping and anti-bacterial functions and preparation method of wound protecting composition |
| CN104383579A (en) * | 2014-11-12 | 2015-03-04 | 无锡中科光远生物材料有限公司 | Wound protection composition with haemostatic and antibacterial functions and preparation method thereof |
| CN105555299A (en) * | 2013-04-22 | 2016-05-04 | 西兰丁姆医疗公司 | Fibrinogen-based tissue adhesive patches |
| CN109381479A (en) * | 2017-08-08 | 2019-02-26 | 于晓彤 | A kind of surgical operation anti-sticking flush fluid |
| CN109985270A (en) * | 2019-04-15 | 2019-07-09 | 江苏南方卫材医药股份有限公司 | A kind of preparation method without latex self-adhering fascia |
| CN111888523A (en) * | 2020-09-08 | 2020-11-06 | 尹振宇 | Preparation method of polylactic acid gel for improving skin |
| CN114177369A (en) * | 2021-12-17 | 2022-03-15 | 无锡中科光远生物材料有限公司 | Blocking anti-adhesion membrane material and preparation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1481907A (en) * | 2003-08-19 | 2004-03-17 | ��������ҽ�ò�������˾ | Carboxymethyl chitosan / carboxymethyl cellulose operative antiblocking film and method for making the same |
| CN1531910A (en) * | 2003-03-25 | 2004-09-29 | Hemostatic wound dressing and its preparing method | |
| WO2005027852A2 (en) * | 2003-09-19 | 2005-03-31 | Fziomed, Inc. | Compositions of polyacids and polyethers and methods for their use in reducing pain |
| CN102908649A (en) * | 2012-11-09 | 2013-02-06 | 无锡中科光远生物材料有限公司 | Anti-adhesion fibrous membrane with hematostatic function |
| CN102921050A (en) * | 2012-11-09 | 2013-02-13 | 无锡中科光远生物材料有限公司 | Preparation method of anti-adhesion fibrous membrane with hemostatic function |
| US20130052236A1 (en) * | 2011-08-30 | 2013-02-28 | Mast Biosurgery | Composite polylactic acid/alginate surgical barrier |
| CN103143050A (en) * | 2013-03-08 | 2013-06-12 | 苏州艾美医疗用品有限公司 | Carboxymethyl chitosan band-aid and preparation method thereof |
-
2013
- 2013-11-21 CN CN201310593829.2A patent/CN103611195B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1531910A (en) * | 2003-03-25 | 2004-09-29 | Hemostatic wound dressing and its preparing method | |
| CN1481907A (en) * | 2003-08-19 | 2004-03-17 | ��������ҽ�ò�������˾ | Carboxymethyl chitosan / carboxymethyl cellulose operative antiblocking film and method for making the same |
| WO2005027852A2 (en) * | 2003-09-19 | 2005-03-31 | Fziomed, Inc. | Compositions of polyacids and polyethers and methods for their use in reducing pain |
| US20130052236A1 (en) * | 2011-08-30 | 2013-02-28 | Mast Biosurgery | Composite polylactic acid/alginate surgical barrier |
| CN102908649A (en) * | 2012-11-09 | 2013-02-06 | 无锡中科光远生物材料有限公司 | Anti-adhesion fibrous membrane with hematostatic function |
| CN102921050A (en) * | 2012-11-09 | 2013-02-13 | 无锡中科光远生物材料有限公司 | Preparation method of anti-adhesion fibrous membrane with hemostatic function |
| CN103143050A (en) * | 2013-03-08 | 2013-06-12 | 苏州艾美医疗用品有限公司 | Carboxymethyl chitosan band-aid and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| ZHIGUO ZHAO等: "High performance ultrafiltration membrane based on modified chitosan coating and electrospun nanofibrous PVDF scaffolds", 《JOURNAL OF MEMBRANE SCIENCE》, vol. 394395, 3 January 2012 (2012-01-03), pages 209 - 217 * |
| 潘仕荣等: "羧甲基壳聚糖用作防止术后粘连的研究", 《中国生物医学工程学报》, vol. 25, no. 3, 30 June 2006 (2006-06-30), pages 277 - 282 * |
| 肖海军等: "羧甲基壳聚糖-羧甲基纤维素防粘连膜的制备及其理化特性", 《中国组织工程研究与临床康复》, vol. 14, no. 38, 17 September 2010 (2010-09-17), pages 7069 - 7074 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105555299A (en) * | 2013-04-22 | 2016-05-04 | 西兰丁姆医疗公司 | Fibrinogen-based tissue adhesive patches |
| CN104383581A (en) * | 2014-11-12 | 2015-03-04 | 无锡中科光远生物材料有限公司 | Wound protecting composition with bleeding-stopping and anti-bacterial functions and preparation method of wound protecting composition |
| CN104383579A (en) * | 2014-11-12 | 2015-03-04 | 无锡中科光远生物材料有限公司 | Wound protection composition with haemostatic and antibacterial functions and preparation method thereof |
| CN109381479A (en) * | 2017-08-08 | 2019-02-26 | 于晓彤 | A kind of surgical operation anti-sticking flush fluid |
| CN109985270A (en) * | 2019-04-15 | 2019-07-09 | 江苏南方卫材医药股份有限公司 | A kind of preparation method without latex self-adhering fascia |
| CN109985270B (en) * | 2019-04-15 | 2021-04-20 | 江苏南方卫材医药股份有限公司 | Preparation method of latex-free self-adhesive bandage |
| CN111888523A (en) * | 2020-09-08 | 2020-11-06 | 尹振宇 | Preparation method of polylactic acid gel for improving skin |
| CN114177369A (en) * | 2021-12-17 | 2022-03-15 | 无锡中科光远生物材料有限公司 | Blocking anti-adhesion membrane material and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103611195B (en) | 2015-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103611195B (en) | Self-adhesion hemostasis anti-adhesion corpus fibrosum | |
| CN103611180B (en) | Preparation method of self-adhesion hemostasis anti-adhesion corpus fibrosum | |
| CN101623517B (en) | Medical anti-sticking membrane and preparation method thereof | |
| EP3119930B1 (en) | Micro-fiber webs of poly-4-hydroxybutyrate and copolymers thereof produced by centrifugal spinning | |
| US8481074B2 (en) | Hemostatic microfibrous constructs | |
| US10022477B2 (en) | Composition for anti-adhesion, surgical mesh composite with anti-adhesion property comprising the same and method for producing thereof | |
| CA2933746C (en) | Medical implants including laminates of poly-4-hydroxybutyrate and copolymers thereof | |
| CN108348660B (en) | Method for manufacturing high-performance suture coated with hyaluronate and high-performance suture thereof | |
| CN102475920A (en) | Preparation method and application of sustained-release system of anti-inflammatory medicament and growth factor | |
| CA2960395C (en) | Oriented p4hb implants containing antimicrobial agents | |
| Awasthi et al. | Recent progress in development of dressings used for diabetic wounds with special emphasis on scaffolds | |
| WO2006019600A2 (en) | Hemostatix microfibrous constructs | |
| KR100953366B1 (en) | Nano fiber for tissue regeneration and fabrication method thereof | |
| CN102908649A (en) | Anti-adhesion fibrous membrane with hematostatic function | |
| KR20200007698A (en) | Biodegradable polymeric thread filler for promoting the formation of collagen in skin and method for preparing the same | |
| EP3142716B1 (en) | Medical devices containing dry spun non-wovens of poly-4-hydroxybutyrate and copolymers with anisotropic properties | |
| KR19990017189A (en) | Method for preparing absorbent suture containing chitosan | |
| CN104436280B (en) | Composite material of potato starch system for stopping bleeding and preventing adhesion and preparation method thereof | |
| KR102655715B1 (en) | Manufacturing method of medical nanosheets using polycaprolactone, medical nanosheets manufactured by this method | |
| CN104383582B (en) | Haemostatic anti-adhesion composite material for hydroxyethyl cellulose system and preparation method of composite material | |
| JP6678255B2 (en) | Biological tissue reinforcing material and artificial dura | |
| CN117503980A (en) | Double-layer nanofiber membrane dressing and preparation method and application thereof | |
| KR20220132365A (en) | Manufacturing method of medical nanosheets using polyvinyl alcohol, medical nanosheets manufactured by this method | |
| IE20070525A1 (en) | A nanofibre product | |
| CN103524747A (en) | P-dioxanone polymer as well as synthesis method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |